Independent report · Precision Oncology / Clinico-Genomic AI

4baseCare: Building India's Cancer Genomics Dataset

May 12, 2026 · By Reena

4baseCare company material

Independent report content

INDEPENDENTREPORT

4baseCare Indian Biotech Precision Oncology Clinico-Genomic AI Series B Bengaluru June 25, 2026 ROUND Series B total close — Rs 128 Cr ($13.3M) S T RU CT URE First close Rs 90 Cr (Jan 2026) | Top-up Rs 38 Cr (Jun 2026)

TO P - UPLEADS growX Ventures | Infosys Innovation Fund (strategic) | Existing investors follow-on FIRSTC LO SELEADS Ashish Kacholia | Lashit Sanghvi | Yali Capital (existing) FY 2 5 REVENUE < Rs 10 Cr (Tracxn/MCA) | Tests/month: ~1,500 | Target: 8,000-10,000

CINU74999KA2018PTC112818

H Q Bellandur, Outer Ring Road, Bengaluru 560103 FOUNDED 2018 | Employees: 270 (Tracxn Apr 2026, +31% YoY) FOUNDERS Hitesh Goswami (CEO) + Kshitij Rishi (COO) KEY VA L I DAT ION MSK iHub (OncoTwin selected) | AIIMS Jammu | Max Healthcare | Maharashtra Govt MoU | Total Raised: $25.9M (8 rounds, 43 investors)

Rupeia Signal Bar — Five Dimensions, Independently Assessed

TECHNOLOGY

Green

CLINICAL VALIDATION

Amber

REVENUE

Red

FINANCIALS

Red

MARKET TIMING

Green

MOSTCRITICALUNVERIFIEDCLAIM

Tracxn data shows FY25 revenue with a "CAGR of -93% in last 1 year." At 1,500 tests/month at reasonable NGS pricing, revenue should be Rs 15-30 Cr — yet MCA-adjacent sources show < Rs 10 Cr. This material discrepancy cannot be resolved without a direct Tofler/MCA P&L download, and it governs the entire

financial case. See Section 4.

RUPEIA 4BASECARE, SERIES B INDEPENDENT REPORT

★ INVESTMENT SUMMARY

EXECUTIVESUMMA RY 4baseCare is India's most advanced precision oncology company, combining

hospital-embedded NGS genomic labs with an AI clinical decision support platform (OncoTwin) and — critically — the world's largest clinico-genomic dataset from non-Caucasian cancer patients. The core insight is structural: non- Caucasian populations make up 70% of global cancer diagnoses but less than 5% of genomic research data. 4baseCare is building the database that will correct this — monetising it through genomic testing fees today (80% of revenue) and platform/pharma data licensing tomorrow. MSK iHub selection validates the platform at the highest global clinical standard. The investment risk is primarily

financial: < Rs 10 Cr annual revenue at Series B close means a long runway to

profitability, and the test-volume growth required (1,500/month to 8,000- 10,000/month) demands flawless execution across 8-10 new country markets simultaneously. COM PA N Y Entity: 4baseCare Genomics Private Limited | CIN: U74999KA2018PTC112818.

HQ: Outer Ring Road, Bellandur, Bengaluru 560103. Founded 2018 (incorporated May 3, 2018). Labs: India (Bengaluru HQ) + Dubai + Nepal + Philippines | 8-10 more countries in 12-18 months. Regulatory: CAP-accredited lab (claimed) | NABL (claimed) | DPDP compliance: not confirmed.

FOUNDERS Hitesh Goswami (CEO): IIT Kharagpur + INSEAD (MBA). Earlier: Bionivid (bioinformatics — founder). Genomics informatics + cancer biomarkers. Public face. Kshitij Rishi (COO): genomics and cancer research. Less publicly profiled. Both share origin in cancer genomics research and prior startup experience (Bionivid). 4baseCare is their second-attempt thesis, refined with domain learnings.

PRODU CT S Genomic Testing (80% of revenue): NGS somatic/germline panels. Tissue, liquid, SoLiQ. TarGT Indiegene: world's first Indian-population-specific cancer panel (1,500+ patient profiling). OncoTwin (AI): digital patient replica, MSK iHub- selected. MTB Intelligence: Molecular Tumor Board AI workspace. Clinical Trials & Drug Discovery (emerging): real-world evidence for pharma.

FINANCIALS ( MCA ) FY25 Revenue: < Rs 10 Cr (Tracxn MCA-adjacent) | EBITDA deeply negative.

CRITICAL: Tracxn reports "CAGR of -93% in last 1 year" — signals a restatement or a genuine decline. Tests/month (FY26 run rate): ~1,500 = ~18,000/yr. At Rs 15,000-25,000 per test, gross potential Rs 27-45 Cr/yr; actual < Rs 10 Cr suggests a pricing, volume, or collection gap. Burn ~Rs 20-30 Cr/yr.

RUPEIA 4BASECARE, SERIES B INDEPENDENT REPORT

CURRENTROUND Series B total Rs 128 Cr ($13.3M). First close (Jan 2026) Rs 90 Cr — Ashish Kacholia, Lashit Sanghvi, Yali Capital. Top-up (Jun 2026) Rs 38 Cr — growX Ventures (lead), Infosys Innovation Fund (strategic). Prior: Speciale Invest, IAN

Fund, BEENEXT, Tremis. Total raised: $25.9M (8 rounds, 43 investors).

USEOFPROCEEDS Global genomics lab expansion (India + 8-10 new countries: Middle East, SEA, LatAm, Central Asia) | OncoTwin scale-up | Hospital partnership deepening | Test volume to 8,000-10,000/month. Allocation undisclosed. NGS sequencer: Rs 2-5 Cr each; 10 countries = Rs 20-50 Cr equipment alone.

RUPEIA INVESTMENT INTELLIGENCE | JUNE 25, 2026 | INDEPENDENT REPORT #003 OF 100

0A CLAIM REGISTER — EVIDENCE GRADING

A = Statutory/regulatory/government | B = Patent/certification/customer-side | C = Independent press/investor | D = Company press release | E = No evidence or conflict

CLAIM SOURCE GRADE RUPEIA ASSESSMENT

Non-Caucasian = 70% of cancer diagnoses but <5% of genomic data CEO Hitesh Goswami + growX CEO Ashish Taneja — multiple press C PROBABLE — widely cited in oncology literature. NIH datasets are 80%+ Caucasian.

Directionally correct and independently supportable. OncoTwin selected for MSK iHub program (Memorial Sloan Kettering)

digitalhealthnews.com (Jan 2026); multiple sources C PROBABLE — MSK iHub is a real, prestigious accelerator. Announcement consistent across

sources. No MSK-direct press release found.

Verify via published cohort list. TarGT Indiegene: world's first Indian- population-specific cancer panel

Company website;

nasscom.coe-iot.com; multiple press D CLAIMED — "world's first" requires patent verification. Developed with ACTREC-Tata Memorial (verifiable). 1,500+ patient dataset claim unaudited.

1,500 genomic tests per month (current) analyticsinsight.net; BW Disrupt; multiple Jun 2026 press C PROBABLE — Multiple independent sources citing same company figure. Not independently audited. Reasonable for a company with labs in 4 countries + hospital partnerships.

Target: 8,000-10,000 tests per month Same sources as above D CLAIMED — Management target. Requires 5-7x volume growth, dependent on lab expansion succeeding in 8-10 countries simultaneously.

Revenue: ~80% from genomic testing whalesbook.com citing

company (Feb 2026)

C PROBABLE — Consistent with stage: testing is current revenue; platform licensing is future. No audited P&L breakdown. Infosys invested Rs 8.3 Cr (2024) via Innovation

Fund

analyticsinsight.net; multiple top-up coverage C VERIFIED — Infosys Innovation Fund

investment confirmed across multiple credible

sources. Rs 8.3 Cr (~$1M) consistent.

RUPEIA 4BASECARE, SERIES B INDEPENDENT REPORT

CLAIM SOURCE GRADE RUPEIA ASSESSMENT

Maharashtra Govt MoU (Mar 31, 2026) — precision oncology centre Express Healthcare Mar 31, B PROBABLE — MoU confirmed by Express Healthcare (credible). MoU is non-binding.

Centre requires land, equipment, staffing. Series B total: Rs 128 Cr ($13.3M) Entrackr; BW Disrupt; analyticsinsight — Jun 2026 A VERIFIED — Multiple tier-1 sources, consistent.

Rs 90 Cr first close + Rs 38 Cr top-up = Rs 128 Cr. AIIMS Jammu + Max Healthcare + Shankara Hospital partnerships Medical Buyer; multiple Jun 2026 press C PROBABLE — Named partners in multiple independent sources. No signed contract/MoU documents confirmed. In-hospital lab model described consistently.

CAP/NABL lab accreditation

Company website (implied) D CLAIMED on website — must verify via NABL

database and CAP directory. Critical for clinical validity. 270 employees, +31% YoY growth Tracxn (Apr 2026) B HIGH CONFIDENCE — Tracxn MCA-adjacent.

270 vs ~200 a year earlier. Consistent with lab- network expansion.

MOSTCRITICALUNVERIFIEDCLAIM — THEREVENUEANOMA LY

Tracxn data shows FY25 revenue with "CAGR of -93% in last 1 year." This is extraordinary — it suggests either (a) FY24 revenue was significantly higher and FY25 collapsed, or (b) a restatement occurred. At 1,500 tests/month at reasonable NGS pricing, revenue should be Rs 15-30 Cr. The fact that MCA-adjacent sources show < Rs 10 Cr is a material discrepancy that demands direct MCA P&L verification before any

investment. This single data point cannot be resolved without a Tofler/MCA direct filing download.

0B FACT-CHECK & CORRECTIONS LOG

FIELD AS STATED VERIFIED POSITION SOURCE

REVENUE

ANOMALY

(CRITICAL)

1,500 tests/month at "Rs 15,000- 25,000 per test" ANOMALY: 1,500 × Rs 20,000 = Rs 3 Cr/month = Rs 36 Cr/yr. Yet Tracxn reports < Rs 10 Cr FY25. One or more of: (1) avg price lower (Rs 4,000-6,000 for basic panels); (2) volume lower than 1,500/month in FY25; (3) high uncollected receivables; (4) revenue recognised only on collection. Must be resolved.

Tracxn MCA FY25; press pricing estimates

FOUNDING YEAR

CONFLICT

Some sources "2019"; others "2018"

SETTLED: CIN U74999KA2018PTC112818 —

"KA2018" = Karnataka, 2018. MCA shows incorporation May 3, 2018. "2019" likely refers to commercial operations or Series A (Illumina Accelerator). Rupeia uses 2018.

Tracxn legal entity; MCA CIN format

INFOSYS

INVESTMENT

STATUS

Some call Infosys "co-lead" of top- up; others say growX led SETTLED: growX Ventures is lead in the top-up.

Infosys participated alongside. Multiple sources confirm "led by growX and Infosys" — Infosys is a co-participant and a follow-on (after Rs 8.3 Cr in 2024).

Entrackr Jun 2026; BW Disrupt

RUPEIA 4BASECARE, SERIES B INDEPENDENT REPORT

FIELD AS STATED VERIFIED POSITION SOURCE

TOTAL FUNDING

FIGURE

$25.9M (Tracxn) vs Rs 128 Cr = $13.3M (press) DISCREPANCY: $25.9M is total cumulative funding across ALL 8 rounds from inception. Rs 128 Cr = $13.3M is Series B only. Both correct for different periods.

Tracxn; BW Disrupt; Entrackr MSK iHub

SELECTION

Some call it "testing," others "partnership" or "validation" CLARIFIED: MSK iHub is a formal accelerator/selection program. "Selected for testing on MSK datasets" = MSK agreed to evaluate OncoTwin on their patient data. A validation opportunity, not a commercial partnership.

Revenue from MSK is not implied. digitalhealthnews.com Jan 2026

LABORATORY

ACCREDITATION

Company claims

CAP + NABL on website UNVERIFIED: NABL database and CAP directory searches not conducted in this report. Critical for clinical validity and hospital partnerships. If unverified, hospital partners may be accepting unaccredited reports — a clinical and regulatory

risk.

Company website (D-

grade only) Data-Room Gap Statement

PRIVATE DATA

NEEDED

PUBLIC PROXY

USED CONFIDENCE INVESTMENT IMPACT

MCA direct P&L FY24 and FY25 (Tofler) Tracxn MCA- adjacent: <Rs 10 Cr FY25 MEDIUM — anomaly unexplained Revenue quality and pricing model cannot be assessed without this.

Lab accreditation certificates (NABL, CAP)

Company website

claims NONE Clinical validity of test reports depends on this; hospital partnerships at risk if unaccredited. Per-test pricing breakdown (basic vs comprehensive)

Industry benchmarks: Rs 4,000-25,000 LOW Revenue model depends entirely on mix shift toward comprehensive panels.

Signed hospital partnership contracts vs MoUs Press release descriptions NONE Revenue pipeline depends on binding contracts, not MoUs.

DPDP (2023) compliance status No public filing found NONE Genomic data = most sensitive personal data.

Cross-border transfer to Dubai/Philippines labs requires explicit DPDP consent framework. Drug/pharma data licensing revenue (any)

Company website

description only NONE Second revenue stream (beyond testing) is entirely unvalidated.

1 COMPANY OVERVIEW

4baseCare was founded in 2018 by Hitesh Goswami and Kshitij Rishi on a thesis that is simultaneously a scientific insight and a business opportunity: the global cancer genomics database is almost entirely built on Caucasian patients from the US and Europe, yet 70% of cancer cases globally occur in non-Caucasian populations. Treatments calibrated on Caucasian genomic data work less effectively for South Asian,

RUPEIA 4BASECARE, SERIES B INDEPENDENT REPORT

Southeast Asian, Latin American and African patients. 4baseCare is building the database that corrects this — and generating revenue along the way by being the genomic testing infrastructure for these populations. The founding team came from bioinformatics (Goswami's prior company Bionivid) and cancer research (Rishi), both with domain expertise that is difficult to replicate. They secured early validation from the most credible possible source: Illumina, the company that manufactures the world's leading NGS sequencing machines, selected them for the 10th Illumina Accelerator cohort in 2019. Being selected by your key equipment vendor as an accelerator company is the equivalent of being selected by ISRO as a launch partner — it signals that the domain incumbent believes you are building something worth supporting.

The business model has three interlocking layers that compound over time. Layer 1 is the hospital- embedded genomics lab: 4baseCare installs or partners with labs inside major hospital systems, dramatically reducing turnaround time and creating a sticky, recurring testing relationship. Layer 2 is OncoTwin: the AI platform trained on real-world patient data from those labs, providing oncologists with treatment

recommendations matched against similar patient outcomes. Layer 3 is the pharma/research data play: once

the dataset reaches sufficient scale and geographic diversity, pharmaceutical companies will pay to access it for drug discovery, clinical trial stratification, and biomarker validation. This three-layer model is the same that Tempus (US) has proven works commercially — Tempus went from testing to platform to pharma data and is now listed on Nasdaq.

2 CORE TECHNOLOGY & PRODUCTS

A. Genomic Testing Portfolio (Current Revenue Source)

PRODUCT TECHNOLOGY CLINICAL USE GRADE

Somatic Profiling (CGP) NGS tumor DNA + RNA from FFPE blocks or liquid biopsy. All solid tumors.

Identifies actionable mutations, fusions, signatures, resistance. Guides targeted/immunotherapy. C (ACTREC collaboration validates Indian dataset)

TarGT Indiegene First Indian-population-specific gene panel. 1,500+ patients' whole exome + transcriptome.

Higher sensitivity for mutations common in Indian populations vs Western panels. C (ACTREC-Tata Memorial = credible partner)

Liquid Biopsy (ctDNA) Circulating tumor DNA from blood — non-invasive.

High-sensitivity mutation detection. Tracks treatment response without repeat biopsies. C (standard tech; specific sensitivity unaudited)

SoLiQ (combined) Simultaneous tissue + liquid + germline analysis.

Overcomes tumor heterogeneity. Most comprehensive single-patient genomic picture. D (proprietary; no peer- reviewed publication found)

HRD Assay (Genomic Scar) Scar-based HRD beyond BRCA-only. Ovarian, breast.

Identifies PARP inhibitor eligibility more accurately than BRCA-only. C (standard assay; implementation unaudited)

Germline+ (Hereditary) Germline sequencing for inherited cancer risk variants.

Inherited risk; treatment sensitivity; family counselling. C (standard tech; India validation claimed)

RUPEIA 4BASECARE, SERIES B INDEPENDENT REPORT

B. OncoTwin — AI Clinical Decision Support OncoTwin differentiates 4baseCare from a pure-play genomics lab. It creates a digital patient replica by integrating genomic data, pathology, radiology, clinical history and treatment outcomes — then matches this "twin" against the real-world outcomes database of similar patients. For an oncologist facing a rare cancer subtype or treatment resistance, OncoTwin provides evidence-based recommendations grounded in what happened to the most similar patients in the database. The Memorial Sloan Kettering iHub selection is the most important validation signal in this company. MSK is the world's leading cancer centre; being selected to test your AI on their patient datasets filters out 99%+ of healthtech companies globally. This is not a commercial partnership — it is a validation opportunity. But if OncoTwin performs well on MSK data, the path to international pharma data licensing opens materially.

ONCOTWINMO AT : THED ATA F LY WHEEL

More tests processed = more data points in OncoTwin = better match accuracy = more hospital partners choose 4baseCare = more tests processed. This is the same compounding mechanism Tempus (US, listed Nasdaq) used to go from $0 to $1.7B revenue over 10 years. 4baseCare is 6-7 years behind Tempus but has a structural advantage Tempus does not: the non-Caucasian genomic dataset is a category Tempus has not prioritised. If 4baseCare builds the definitive non-Caucasian cancer genomics dataset, they own a moat no US company can replicate without spending decades and billions building South Asian, Southeast Asian, and Latin American cohorts.

3 FUNDING HISTORY & INVESTOR BEHAVIOUR FORENSICS

ROUND DATE AMOUNT LEAD / KEY INVESTORS RUPEIA NOTES

Pre-Seed / Grants 2018-19 ~$0.5M est. Illumina Accelerator; Karnataka Elevate (Rs 35 lakh); AISEA (DST)

Non-dilutive early validation. Illumina backing = equipment vendor endorsement. Pre-Series A 2019 ~$2M Mount Judi Ventures; growX Ventures (original entry); Season Two; First In Ventures; angels growX invested at this stage — now leading the Series B top-up 7 years later. Rare continuity signal.

Series A 2021-22 est. ~$5-7M est. Speciale Invest; IAN Fund; BEENEXT; MedTech Innovator APAC; Appscale Academy Speciale Invest = India's premier deeptech fund. IAN = India's oldest angel network. Strong deeptech credibility.

Infosys Innovation

Fund

2024 Rs 8.3 Cr (~$1M) Infosys (strategic) Strategic corporate investor. Digital health + AI genomics is adjacent to Infosys's AI services. Customer or partnership signal.

Series B First Close Jan 2026 Rs 90 Cr Ashish Kacholia (lead); Lashit Sanghvi; Yali Capital Kacholia = India's most followed HNI stock investor.

Backing a private healthtech is unusual and signals conviction. Series B Top- Up Jun Rs 38 Cr growX Ventures (lead); Infosys (follow-on) SERIES COMPLETE. Total Series B Rs 128 Cr ($13.3M).

43 investors across 8 rounds. TOTAL $25.9M (all rounds) 43 investors (18 institutional + 25 angel) 8-year funding journey. Still pre-profitability. Series C likely FY28 if test volume delivers.

RUPEIA 4BASECARE, SERIES B INDEPENDENT REPORT

GROWXCONTINUITYSIGNAL — MOSTSIGNIFICANTPOSITIVE

growX Ventures invested in 4baseCare's Pre-Series A (~2019) and is now co-leading the Series B top-up (Jun 2026) — 7 years of continuous investor confidence. A seed-stage investor who stays through 7 years and leads the growth round has seen the full company journey: early pivots, COVID disruption to lab operations, the data-building phase, and the hospital partnership model. Their continued lead conviction is the strongest possible inside view available.

ASHISH KA CHOLIAENTRY + INFO SYS STR AT EGICSIGNAL

Kacholia is India's most prominent retail equity investor. His entry into a private biotech as co-lead of a Series B is unusual — likely either a pre-IPO play with a clear BSE/NSE SME listing path, or domain confidence from independent diligence; either is positive. Separately, Infosys Innovation Fund investing Rs 8.3 Cr (2024) and participating again in the Jun 2026 top-up is strategic, not financial: OncoTwin could become an Infosys-delivered solution to hospital systems globally — giving Infosys a precision oncology product and 4baseCare an enterprise distribution channel. This strategic alignment is underappreciated in all current coverage.

4 FINANCIAL FORENSICS

REVENUED ATA ISANOMALOUS — RUPEIACANNOTRESO LV EWITHOUTTOFLER

Tracxn reports FY25 revenue < Rs 10 Cr with "CAGR of -93% in last 1 year." This is extraordinary for a

company that claims 1,500 tests/month, just closed Rs 128 Cr Series B, and has 270 employees. A -93%

revenue CAGR means FY24 revenue was approximately Rs 130+ Cr (which cannot be true), OR there was a restatement/reclassification, OR the MCA filing used a different revenue recognition approach. This is the highest-priority financial diligence item. Every number below carries HIGH UNCERTAINTY until the MCA P&L is directly verified via Tofler.

Revenue Reconstruction Attempt

METHOD CALCULATION

ESTIMATED

REVENUE IMPLICATION

Bottom-up: volume × price 18,000 tests/yr × blended Rs 8,000- 15,000 (basic Rs 4,000 to comprehensive Rs 25,000+)

Rs 14-27 Cr/yr (FY26 run rate) Current revenue likely Rs 14-27 Cr, not < Rs 10 Cr. Either volume was lower in FY25 or price lower than press suggests.

Comparable: Datar Cancer Genetics Rs 2,300/test avg × 18,000 tests Rs 41 Cr/yr If Datar pricing applies, revenue should be Rs 30-40 Cr. < Rs 10 Cr MCA suggests much lower FY25 volume.

MCA-reported figure Tracxn citing MCA: < Rs 10 Cr FY25 < Rs 10 Cr Authoritative. Means either ~600-800 tests/month in FY25, OR Rs 1,000-2,000/test, OR poor collection.

FY26 trajectory (press-implied) 1,500 tests/month from Jan 2026 Rs 20-30 Cr FY26 trajectory FY26 may show 3-5x revenue jump from FY25 if volume scaling is accurate. Series B is funding this.

RUPEIA 4BASECARE, SERIES B INDEPENDENT REPORT

Key Financial Metrics (Estimates — Verify via Tofler)

METRIC ESTIMATE CONFIDENCE FLAG

FY25 Revenue < Rs 10 Cr (MCA) | Rs 14-27 Cr (Rupeia est.) LOW — gap unexplained HIGHEST PRIORITY — verify via Tofler FY26 Revenue (trajectory)

Rs 20-35 Cr (Rupeia est.) MEDIUM Still 3.5-7x below the 8,000-10,000/month target (~Rs 100-150 Cr) Gross margin 40-60% MEDIUM Higher than diagnostics (IP in interpretation); lower than pure software (lab ops)

Annual operating burn Rs 20-35 Cr/yr MEDIUM On Rs 128 Cr: 4-6 yrs theoretical. But lab expansion capex consumes Rs 30-60 Cr more.

Real runway (Series B) 2.5-4 years (FY29) MEDIUM Series C needed by FY28-29 depending on revenue growth rate Total funding efficiency $25.9M raised; < Rs 10 Cr FY25 = ~$1.2M revenue/$25.9M LOW 0.05x revenue/funding is very low — typical of data- building biotech but requires monitoring The Tempus benchmark: Tempus (US precision oncology, Nasdaq 2024) raised $1.3B before reaching profitability over ~10 years. 4baseCare has raised $25.9M and is 8 years old — ahead of Tempus on capital efficiency for the data-building phase, but far behind on scale. The question is whether $25.9M + Series B is sufficient to reach the scale threshold where pharma data licensing becomes meaningful.

5 PIPELINE-TO-CASH CONVERSION MODEL

RUPEIAPROPRIE TA RYANA LYS I S

4baseCare has three revenue streams with very different conversion timelines and confidence levels. This model separates them to show which capital goes toward near-term cash and which is long-dated optionality.

REVENUE

STREAM CURRENT STATUS CONVERSION

CASH (24

MO) KEY RISK

Genomic testing (hospitals & direct) ~1,500 tests/month, ~Rs 14-27 Cr run rate 90% (B2B hospital, 60-90 day)

Rs 12-24 Cr collected Customer concentration unknown. No named customers confirmed. If top 3 = 70%, loss of one is material.

In-hospital lab model (India deepening) AIIMS Jammu, Max, Shankara confirmed 60-70% (some MOUs don't deploy)

Rs 10-20 Cr FY27 Each hospital needs trained staff, equipment, IT integration. 6-12 months to steady state.

International lab expansion (8-10 countries) Dubai, Nepal, Philippines. Expanding ME, SEA, LatAm, Central Asia.

30-50% (12-24 mo to volume; per-country regulatory) Rs 15-40 Cr FY27-28 Each country needs local regulatory approval, lab cert, hospital partnerships, local team. 8-10 simultaneously is extraordinarily complex.

OncoTwin platform licensing 0 disclosed paid contracts 10-20% of users convert in 2 yrs Rs 5-15 Cr FY27-28 Hospital SaaS in India is notoriously hard to monetise. Medical directors prioritise clinical validation over cost.

Pharma/CRO data licensing 0 disclosed deals. MSK iHub = validation only.

5-10% of prospects close in 24 mo Rs 10-30 Cr FY28-29 Critical mass: typically >50,000 well- annotated records in the indication. May reach by FY27-28.

RUPEIA 4BASECARE, SERIES B INDEPENDENT REPORT

Total expected cash (24 months, FY26-FY28): Rs 70-130 Cr. Against operating burn Rs 30-50 Cr/yr plus expansion capex Rs 30-60 Cr = Rs 120-220 Cr outflow. Series B Rs 128 Cr + revenue Rs 70-130 Cr = Rs 198-258 Cr available. Against Rs 120-220 Cr outflow = positive to slightly positive through FY28. This is tight. Revenue growth must begin materialising by Q3 FY27 for the Series C to be avoided before FY28-29.

6 MARKET OPPORTUNITY

SEGMENT SIZE / GROWTH 4BASECARE ENTRY RUPEIA ASSESSMENT

India Precision Oncology / NGS Testing Rs 1,200-1,800 Cr by 2028 (est.); CAGR ~25-30% Hospital-embedded NGS labs + direct testing. TarGT Indiegene Indian-specific.

HIGH CONVICTION. 1.4M new cancer cases/yr (ICMR 2022). Genomic testing penetration <5% of eligible. Huge room. Middle East (UAE, Saudi, Kuwait, Oman)

$800M-1.2B precision diagnostics by 2028; high per-capita spend Dubai lab operational. GCC ministers pushing precision medicine nationally.

HIGH CONVICTION — GCC governments mandating precision medicine. Deep pockets, import all genomic testing currently. Southeast Asia (Philippines, Thailand, Indonesia, Vietnam)

$600M-900M by 2028; fragmented, fast- growing Philippines lab operational.

Partnership-led. MEDIUM — per-country regulatory complexity. Philippines FDCA slow. Thailand/Vietnam have stronger genomics infrastructure.

Latin America (Brazil, Mexico, Colombia) $500M-800M by 2028; Brazil dominant No labs yet. Series B expansion capital.

LOW-MEDIUM — Brazil ANVISA 18-24 mo minimum. US labs (Quest, LabCorp) already in Brazil. India cost may not suffice. Global pharma data licensing $2B-4B by 2028 for non- Caucasian genomic data (emerging)

OncoTwin dataset as the non- Caucasian cancer genomics database for pharma R&D HIGH but LONG-DATED — 5-10 year opportunity. Pharma pays $50K-$500K per

deal. Needs 50,000+ records. Target FY28-29.

SOM Reality Check: India + Middle East + Philippines = addressable ~Rs 3,500-5,000 Cr by FY28. At 3-5%

market share (realistic for a 270-person company with Rs 128 Cr capital), revenue = Rs 100-250 Cr —

achievable by FY28-29 if lab expansion succeeds. It requires 5-7x growth from current FY26 trajectory — aggressive but not unprecedented (Metropolis, Thyrocare, SRL all grew 30-50%/yr during similar expansion phases).

7 COMPETITIVE ANALYSIS

7A. Precision Oncology Competitor Table

COMPETITOR HQ

REVENUE /

SCALE 4BASECARE ADVANTAGE 4BASECARE DISADVANTAGE

Tempus AI

(NASDAQ: TEM)

USA $1.7B revenue (FY24); 200,000+ patients Non-Caucasian data uniqueness; India cost base; emerging-market first-mover 10-year head start; $1.3B raised; listed; $100M+ pharma partnerships Foundation Medicine (Roche)

USA >200,000 tests/year Hospital-embedded model; Indian population specificity FDA-approved companion diagnostics (regulatory moat); Roche distribution; 15- year heritage Guardant Health

(NYSE: GH)

USA $700M+ revenue (FY25 est.) Tissue + liquid combined (SoLiQ); emerging-market pricing; local data First FDA-approved liquid biopsy CGP; CLIA-certified; cancer screening entry Datar Cancer Genetics (India)

India ~Rs 70 Cr revenue; BSE-listed AI platform (OncoTwin) vs pure testing; India-population dataset Listed (liquidity, transparency); 15+ years; larger volume; brand recognition

RUPEIA 4BASECARE, SERIES B INDEPENDENT REPORT

COMPETITOR HQ

REVENUE /

SCALE 4BASECARE ADVANTAGE 4BASECARE DISADVANTAGE

MedGenome (India + USA) India / USA $20M+ revenue (est.) OncoTwin AI; broader oncology scope; hospital-embedded model US FDA lab certification; broader hereditary genetics; US diaspora market Strand Life Sciences (India)

India (Bengaluru) Rs 30-50 Cr est.; 400+ employees OncoTwin AI layer; emerging-

market expansion; data uniqueness

Larger, older, more employees; bioinformatics heritage; report depth 7B. Capability Matrix — Yes / No / Partial

CAPABILITY 4BASECARE TEMPUS FOUNDATION GUARDANT DATAR MEDGENOME STRAND

NGS genomic testing operational YES YES YES YES YES YES YES AI clinical decision support platform YES YES PARTIAL PARTIAL NO NO PARTIAL Non-Caucasian population-specific dataset

YES NO NO NO PARTIAL PARTIAL NO

Hospital-embedded in-lab model YES PARTIAL NO NO NO NO NO Liquid biopsy (ctDNA) YES YES YES YES YES PARTIAL PARTIAL Pharma data licensing active NO YES YES PARTIAL NO NO NO FDA/CLIA certified laboratory NO YES YES YES NO YES NO NABL/CAP India accreditation PARTIAL ? ? ? YES YES YES Listed company (public liquidity) NO YES ? YES YES NO NO International labs (4+ countries) YES PARTIAL NO PARTIAL NO PARTIAL NO Molecular Tumor Board (MTB) AI workspace

YES PARTIAL NO NO NO NO NO

Tier-1 global cancer centre validation (MSK)

YES YES YES YES NO NO NO

India-population cancer gene panel YES NO NO NO PARTIAL PARTIAL PARTIAL

NOGLOBALCOMPETITORHASALLTHREE

4baseCare is the only company globally with all three simultaneously: (1) non-Caucasian population- specific dataset; (2) hospital-embedded in-lab model (vs centralised testing); (3) AI MTB workspace for clinical decision making. Tempus has the AI. Foundation Medicine has the FDA approvals. Datar has the India brand. None has all three in the non-Caucasian emerging-market context. This is the genuine competitive differentiation.

8 MOAT ANALYSIS — HALF-LIFE & EXPIRY MAP

CLAIMED MOAT VERIFICATION DURABILITY EXPIRY TRIGGER KEY THREAT

Non-Caucasian cancer genomics dataset (data moat) PROBABLE — dataset exists; scale/quality unaudited 7-10 years (if maintained at scale)

Day Tempus or Foundation Medicine makes an acquisitive India/SEA entry to buy into this dataset No single competitor has prioritised non-Caucasian genomics at scale.

But Tempus international expansion could arrive by FY28-30.

RUPEIA 4BASECARE, SERIES B INDEPENDENT REPORT

CLAIMED MOAT VERIFICATION DURABILITY EXPIRY TRIGGER KEY THREAT

Hospital- embedded model (switching cost) PROBABLE — hospital names confirmed in press 3-5 years per partnership Day a hospital installs its own NGS lab or a competitor offers a better in- hospital solution Apollo building own genomics; AIIMS Delhi has NGS lab. As sequencer costs fall (now ~Rs 50 lakh vs Rs 3 Cr), self-sufficiency becomes viable.

Infosys strategic relationship (distribution) VERIFIED (investment confirmed)

3-5 years (depends on formalisation) If Infosys does not formalise a distribution/partnership beyond equity

Investment ≠ partnership. Without a

formal Infosys reseller agreement for OncoTwin, this moat is potential, not actual. India-population gene panel (TarGT Indiegene)

PROBABLE —

collaboration real; no peer-reviewed publication 5-7 years Competing Indian-specific panel from a well-funded competitor (MedGenome, Strand, AIIMS spinout)

GenotypicTech, MedGenome, and IndiGen (govt project, 10,000 Indians) all building Indian genomic databases.

MSK iHub validation (credibility moat) PROBABLE — selection confirmed; commercial outcome unknown 1-3 years (validation window)

If iHub evaluation does not lead to a formal MSK partnership or publication within 24 months "Selected for testing" ≠ "MSK partnership." If OncoTwin underperforms on MSK data, the association could become negative.

9 CUSTOMER INTELLIGENCE & BUSINESS TRACTION

CUSTOMER / PARTNER RELATIONSHIP TYPE PAID? GRADE

AIIMS Jammu In-hospital genomics lab partner Lab partnership (equipment + testing service) YES — testing fees per patient B Max Healthcare (India) In-hospital lab partner Lab partnership (same model)

YES — testing fees B Shankara Hospital (India) In-hospital lab partner Lab partnership YES — testing fees B Memorial Sloan Kettering (USA)

MSK iHub — OncoTwin selected for dataset testing Validation program — dataset access NO (evaluation, not commercial)

B Maharashtra Government MoU for precision oncology centre Non-binding MoU NO (MoU only) C ACTREC-Tata Memorial Centre

Research collaboration — TarGT

Indiegene development Academic research collaboration NO (grants-based) B Infosys Strategic investor (Rs 8.3 Cr 2024 + follow-on 2026)

Corporate strategic investor YES (investment) A International labs (Dubai, Nepal, Philippines)

Operating labs in these markets Own lab operations

(supplier side) YES — recurring tests in each market C

CUSTOMERCONCENTR AT IONRISK

4baseCare's current paying customers appear concentrated in 3-4 Indian hospital partnerships plus its own international labs. In genomic testing, hospital partnership revenue depends on cancer-patient volumes at that specific hospital and its adoption rate of genomic testing. If AIIMS Jammu or Max slows testing volumes (budget cuts, staff turnover, competitive alternative), concentration risk is high. Require customer revenue breakdown (top-3 customers as % of total) before investment.

RUPEIA 4BASECARE, SERIES B INDEPENDENT REPORT

10 RISK ANALYSIS

RISK SEVERITY DETAIL & MITIGANT RESIDUAL

Revenue anomaly (MCA < Rs 10 Cr vs implied Rs 27 Cr) CRITICAL Tracxn MCA shows < Rs 10 Cr FY25 with -93% CAGR.

Inconsistent with 1,500 tests/month at market pricing. Possible: lower volume, lower pricing, revenue- recognition issue, or restatement. Mitigant: download Tofler MCA P&L before investment.

NOT RESOLVABLE

without direct MCA verification. Do not invest until explained. International lab expansion (8-10 countries simultaneously)

HIGH Simultaneous entry into ME, SEA, LatAm, Central Asia is one of the most operationally complex tasks in healthtech — each country needs regulatory approval, hospital partnerships, local staff, billing, consent frameworks, cross-border data compliance. Most companies fail attempting this simultaneously.

Mitigant: Dubai and Philippines operational shows it can be done one-at-a-time. HIGH — likely to slip to 3-4 countries in 18-24 months. Projections must be probability-weighted by country.

DPDP (2023) compliance HIGH Genomic data is the most sensitive personal data under DPDP. Cross-border transfer to Dubai/Philippines labs requires explicit consent + government-approved framework. No DPDP framework publicly confirmed.

Mitigant: DPDP rules still being finalised; compliance window exists but is closing. HIGH — existential for cross-border genomics.

Failure could suspend international data transfer underpinning the lab model.

Lab accreditation

(NABL/CAP)

verification

MEDIUM-

HIGH If labs are not NABL/CAP certified, clinical reports may not be accepted for treatment decisions — a clinical and legal liability. Mitigant: website claims accreditation; hospital partnerships imply acceptance.

MEDIUM — verify via NABL database and CAP directory before

investment.

OncoTwin monetisation (SaaS in Indian hospitals) MEDIUM Hospital SaaS monetisation in India is notoriously difficult: IT decision-makers are non-clinical; clinical decision-makers are not buyers; budgets are commodity-driven. Tempus spent 7 years monetising in the well-funded US market. Mitigant: Infosys relationship could become a reseller channel (not formalised).

MEDIUM — platform revenue is the high- margin future. If it takes 5+ years, "platform

company" multiples are

premature. Competition from IndiGen + government genomics MEDIUM IndiGen sequenced 10,000 Indian genomes by 2022.

ICMR building national cancer genomic databases. If government opens Indian genomic data (open-access), TarGT advantage collapses. Mitigant: clinical annotation + real-world outcomes (4baseCare's value- add) is the moat; raw sequencing is not.

MEDIUM — monitor IndiGen/ICMR data- sharing policy. Key-person risk (Hitesh Goswami)

MEDIUM Goswami is the public face, fundraiser and vision holder; all investor communications are Goswami- driven. Rishi (COO) is less publicly profiled. Mitigant: both founders committed; biotech founding teams typically have longer horizons.

MEDIUM — dual founder

structure provides some

buffer.

Sector: CDSCO

approvals for companion diagnostics MEDIUM For OncoTwin to become standard of care (not optional support tool), it needs CDSCO SaMD approval. Without it, hospitals use OncoTwin as a recommendation tool with liability remaining with the physician. Mitigant: SaMD framework is nascent; first-movers can shape it.

MEDIUM — CDSCO

SaMD pathway is 18-36 months. Required for full clinical adoption.

RUPEIA 4BASECARE, SERIES B INDEPENDENT REPORT

11 TEAM, GOVERNANCE & PEOPLE INTELLIGENCE

DIMENSION HITESH GOSWAMI (CEO) KSHITIJ RISHI (COO)

Education IIT Kharagpur (Biotech) + INSEAD (MBA) — VERIFIED (LinkedIn) Genomics/cancer research background — less publicly documented Prior company Bionivid (bioinformatics) — founder. MCA shows Bionivid as prior. Commercial outcomes not publicly known.

Co-founder of 4baseCare from inception Domain credibility Strong: IIT + INSEAD + Illumina Accelerator + ACTREC + MSK iHub. Full-stack genomics-to-AI. Operational execution (COO). Likely runs lab operations and clinical partnerships.

Public statement consistency Consistent across interviews (BW Disrupt, Inc42, ET Jun 2026). Core message stable since 2019.

Not independently quoted in press. External communications through Goswami. Key-person risk HIGH — only external-facing founder. MEDIUM — internal operations; lower public exposure.

C U LT URE & HEADCOUNTFORENSICS

Glassdoor data is limited (fewer than 10 reviews). The most credible culture proxy is the 8-year founder commitment and the ACTREC/Tata Memorial research relationship — both suggesting a research-first, mission-driven culture appropriate for clinical genomics but which can create commercial-execution challenges as the company transitions to sales-driven growth. Headcount: Tracxn reports 270 employees (Apr 2026), up 31% YoY from ~206 — consistent with Series A-to-B transition and international lab expansion. The transition risk: leadership's background is technical/research, not enterprise sales. Verify whether 4baseCare has hired a Chief Commercial Officer / VP Sales with hospital-system enterprise sales experience.

Board & Governance (Estimated)

MEMBER CAPACITY SIGNIFICANCE

Hitesh Goswami Co-Founder & CEO (executive) Vision + strategy + fundraising + hospital BD Kshitij Rishi Co-Founder & COO (executive)

Operations + clinical + lab management Ganapathy Subramaniam Board member Yali Capital founder. Deep-tech VC (semiconductor/chip design expanded to healthcare).

growX Ventures representative Expected post-Series B Ashish Taneja (growX founder) likely takes observer/board rights as repeat investor and Series B lead.

RUPEIA 4BASECARE, SERIES B INDEPENDENT REPORT

12 VENDOR / PAYMENT STRESS INDEX & LEGAL / COMPLIANCE

Vendor / Payment Stress Index

SIGNAL FINDING RISK INTERPRETATION

Trade payables / receivables MCA balance sheet not directly accessed — must verify via Tofler UNKNOWN Hospital receivables typically 60-90 day cycles. If hospitals delay payment, working-capital stress can be severe.

Key input dependency: NGS sequencers (Illumina)

Illumina is the global sequencer monopolist (~80% share). Equipment Rs 50L-5Cr; reagents Rs 3,000- 8,000/test.

HIGH — single- supplier dependency Illumina backed 4baseCare (Accelerator) — likely preferential pricing. But Illumina raised reagent prices 30-40% in 2022-23. If repeated, gross margin compresses.

EPFO compliance EPFO portal not accessed UNKNOWN 270 employees across 4 countries — India payroll compliance via EPFO must be verified. International payroll is separate. Cross-border data transfer costs India-Dubai-Philippines genomic data flow. DPDP 2023 not fully implemented; Data Protection Board not yet operational.

HIGH — structural legal gap Not just a compliance cost — an operational legality question. Multi-country labs with Indian patient data flowing between them need a legal framework that may not yet exist.

Lab equipment amortisation NGS sequencer depreciation Rs 10- 15 Cr/yr for a full-scale lab (20,000+ tests/yr)

MEDIUM —

capital-intensive 8-10 countries = 8-10 sequencers = Rs 80-150 Cr equipment outlay. Not in any public financial estimate of 4baseCare.

Legal & Compliance Surface Map

AREA FINDING RESIDUAL RISK

Litigation No public litigation found against 4baseCare or founders Low probability for an 8-year-old biotech with academic collaborators Lab accreditation

(NABL/CAP)

CLAIMED on website — NOT VERIFIED in this report If unaccredited: reports may be inadmissible; hospital partnerships at regulatory risk. International labs (Dubai, Philippines) specifically must be CAP accredited.

DPDP 2023 compliance No public compliance framework disclosed HIGH — cross-border genomic data transfer is existential

risk once DPDP Rules finalised

CDSCO SaMD registration (OncoTwin) Not confirmed. Likely operates as a decision- support tool, not a certified medical device.

MEDIUM — without SaMD approval, liability for treatment decisions sits with physicians, limiting adoption MCA filing compliance Active. AGM held Sep 30, 2024. CIN

U74999KA2018PTC112818.

Compliant to last AGM. Verify FY25 filing status. International regulatory (Dubai DHA, Philippines FDA)

Dubai lab operational = DHA approval likely. Philippines FDA clearance required. Verify per country; assume approvals in place if labs operational, but confirm documentation.

13 VALUATION UNDERWRITING — WHAT WOULD NEED TO BE

TRUE

Valuation is not publicly disclosed. Rupeia estimates based on the Rs 128 Cr Series B at typical Indian

healthtech Series B multiples (20-40x forward, or 8-15x trailing for high-growth).

RUPEIA 4BASECARE, SERIES B INDEPENDENT REPORT

BASIS CALCULATION

IMPLIED POST-

MONEY CONFIDENCE

Trailing multiple (FY25 < Rs 10 Cr × 40x) Rs 10 Cr × 40x Rs 400-600 Cr LOW — anomaly makes unreliable Forward multiple (FY26E Rs 25 Cr × 30x)

Rs 25 Cr × 30x Rs 700-900 Cr MEDIUM — if FY26 trajectory confirmed Comparable: Tempus IPO EV/Revenue Tempus 8.8x; India discount 60% + India-growth premium 5x Rs 400-600 Cr LOW — Tempus 50x larger

Transaction comp: MedGenome

(~7x) FY26 Rs 25 Cr × 7x Rs 150-250 Cr MEDIUM — closest Indian comp VC return math (Series B, 3-5x) Entry Rs 500 Cr, exit Rs 1,500-2,500 Cr in 5-7 yrs Rs 400-700 Cr MEDIUM

TRE AT ASINVESTMENT - S TA GEBIOTECH

Because 4baseCare has not disclosed post-Series B valuation and MCA revenue is below Rs 10 Cr, applying precise multiples is misleading. Rupeia's best estimate: Rs 400-700 Cr post-money (~$48-84M), consistent with the Rs 128 Cr Series B representing a 15-20% equity stake. The correct framing is not "is this cheap or expensive at X multiple" but "does the clinical validation (MSK iHub, hospital partnerships) and data-moat thesis justify the capital required to reach the data-licensing phase?" Scenarios: What Would Need To Be True

SCENARIO KEY ASSUMPTION

FY29E

REVENUE

EXIT

MULTIPLE

EXIT EV

RETURN ON RS 700 CR

POST-MONEY

BEAR Revenue anomaly is real. International expansion fails in 5+ countries. OncoTwin not monetised. Pharma licensing takes 7+ years. Rs 30-50 Cr (testing only, India)

8x (diagnostics) Rs 240- 400 Cr 0.35-0.57x. Capital loss for Series B.

BASE FY25 anomaly resolved (Rs 20-30 Cr actual). 4-5 international markets by FY28. Hospital partnerships 30-50. OncoTwin initial licensing. Rs 120-180 Cr 12-15x (platform premium)

Rs 1,440- 2,700 Cr 2-4x. 20-30% IRR. Adequate for HNIs; marginal for institutional VC.

BULL Data flywheel activates. 8+ countries by FY28. Pharma data licensing Rs 30-50 Cr/yr by FY29. Infosys distribution. IPO at Tempus-like premium.

Rs 300-500 Cr 20-25x (platform+data) Rs 6,000- 12,500 Cr 8-18x. 40-60% IRR.

Transformative.

14 EXIT ANALYSIS

EXIT ROUTE TIMELINE VALUATION BASIS NAMED CANDIDATES PROBABILITY

India BSE / NSE

SME IPO

FY28-30 15-25x forward revenue. Healthcare + AI + oncology narrative. Kacholia involvement read as pre-IPO signal. BSE MainBoard or NSE Emerge. MEDIUM-HIGH Strategic — global diagnostics major FY27-30 10-20x revenue. Comparable: Roche/Foundation Medicine ~12x.

Illumina (existing relationship; data + testing vertical integration). Abbott. bioMerieux. Exact Sciences.

MEDIUM

Strategic — Indian healthcare major FY27-29 8-15x revenue Apollo Hospitals (building precision medicine). Manipal. Aster DM. Narayana Hrudayalaya.

MEDIUM

US-India pharma licensing (not acquisition) FY28-30 $5-50M per data deal Novartis, AstraZeneca, Pfizer, GSK — any pharma with South Asian population drugs in development.

MEDIUM-HIGH (for data deals)

RUPEIA 4BASECARE, SERIES B INDEPENDENT REPORT

EXIT ROUTE TIMELINE VALUATION BASIS NAMED CANDIDATES PROBABILITY

PE secondary / growth equity FY27-29 3-5x invested for early investors Quadria Capital. Asia Healthcare Holdings. Carlyle Asia healthcare.

MEDIUM if IPO delayed

15 DEAL TERMS & FOUR GATING QUESTIONS

ROUND Series B total close — Rs 128 Cr ($13.3M). First close Rs 90 Cr (Jan 2026) + top-up Rs 38 Cr (Jun 2026). VA LUAT ION NOT PUBLICLY DISCLOSED. Rupeia estimate: Rs 400-700 Cr post-money (~$48-84M). Based on VC return math and Indian healthtech Series B comparables. Must confirm directly with company.

INVES TO R S First close: Ashish Kacholia (co-lead), Lashit Sanghvi, Yali Capital (existing). Top- up: growX Ventures (lead), Infosys Innovation Fund (strategic follow-on). Existing: Speciale Invest, IAN Fund, BEENEXT, Tremis. Total: 43 investors across all rounds (18 institutional + 25 angel) — unusually broad for Series B.

CAP TA BLE ( EST. ) Founders 20.33% (Tracxn, post-Series B) | Funds 42.58% (growX, Speciale, Yali, IAN, BEENEXT) | Enterprises 19.76% (Infosys likely here) | Angels 10.45% (Kacholia, Sanghvi). Founders at 20.33% after 8 rounds is low — risk of demotivation if not offset by ESOP/vesting acceleration.

RU N WAY Series B Rs 128 Cr. Operating burn Rs 20-30 Cr/yr. Lab expansion capex (8-10 countries) Rs 30-60 Cr. Total outflow Rs 50-90 Cr/yr. Real runway: 1.4-2.5 years. Series C needed by FY28-29 AT THE LATEST. Revenue offset (Rs 20-35 Cr FY26 growing to Rs 60-100 Cr FY27-28) reduces but does not eliminate Series C need.

# QUESTION VERIFICATION METHOD KILL CONDITION RESOLUTION PATH

1 Revenue anomaly explanation Download Tofler FY24 and FY25 P&L directly (Rs 300-500/yr).

Reconcile against 1,500 tests/month and pricing. If MCA confirms < Rs 10 Cr FY25 with no explanation: pricing and volume assumptions in all projections are wrong.

Complete restart of financial model. Ask CEO directly: "Tofler shows < Rs 10 Cr FY25. Your website says 1,500 tests/month. What is the reconciliation?" The quality of the answer determines confidence in all

financial claims.

2 NABL/CAP

accreditation verification Search NABL database (nabl.gov.in — free) for "4baseCare." Search CAP international directory for Indian labs.

If no NABL/CAP accreditation: hospital partners may be taking legal risk; reports may be inadmissible; the hospital- embedded model is legally fragile.

Request accreditation certificates. Cross-verify with NABL database. 3 DPDP 2023 compliance plan Ask: "What is your legal framework for cross-border transfer of patient genomic data from India to Dubai and Philippines under DPDP 2023?" If no DPDP framework exists: international lab model may need restructuring once Rules are finalised. Could require re- consent or restructured data flows.

Rules still being finalised — current window allows compliant-by-design. Ask for the legal counsel's DPDP roadmap.

RUPEIA 4BASECARE, SERIES B INDEPENDENT REPORT

# QUESTION VERIFICATION METHOD KILL CONDITION RESOLUTION PATH

4 Founder dilution and ESOP adequacy At 20.33% founder ownership after 8 rounds, request ESOP pool size, recent grants, vesting, any prior founder liquidity.

If founders' effective economic stake is below 10% fully diluted with no ESOP refresh, motivation risk for the long journey to profitability is material.

Refresh ESOP pool as a condition of

investment. Ensure founders retain

>15-20% diluted going forward.

16 INVESTOR CLASS ANALYSIS

RUPEIASECTION — UNIQUETOTHISREPORT

Each investor class faces fundamentally different risks and rewards from the same 4baseCare position. For Individual Investors (HNIs / Angels / UHNI) 4baseCare is a materially different investment from Skyroot or Ethereal Machines for individual investors. The risk is not binary — a Vikram-1-equivalent failure that destroys 80% of capital in 6 months. The risk is long-dated: the company could operate for 5-7 more years, raise 1-2 more rounds, deliver moderate growth, and exit at 1-2x on the Series B entry price. This "zombie outcome" — not failure, but insufficient return — is the specific risk for individual investors in precision oncology. The opportunity is equally long-dated: if OncoTwin reaches Tempus-equivalent status (even at 20% of Tempus's scale) and the data-licensing business activates, the return is 8-15x over 8-10 years — genuinely transformative for a Rs 1-3 Cr allocation. The Ashish Kacholia signal is important context: Kacholia typically exits within 2-5 years, so his entry into a private company suggests a clear view on exit timing — likely an SME/MainBoard BSE listing within 3-5 years, providing liquidity not typically available in private biotech. However, the revenue anomaly (< Rs 10 Cr FY25) must be resolved before any individual invests. If the MCA P&L shows substantially lower revenue than the test-volume-implied figure, the Series B valuation is unsupported by fundamentals.

For Family Offices (Healthcare / Pharma Background Preferred) Family offices with healthcare background are the best-fit investor for 4baseCare at this stage — better than pure-financial VCs and better than individuals without domain insight. The rewards are threefold. First, the data-moat thesis rewards patience: building the definitive non-Caucasian cancer genomics dataset takes 5- 10 years, and a family office with no LP exit pressure can hold through the data-building phase and participate in the pharma-licensing phase when valuations step up dramatically. Second, strategic value: a family office connected to Indian hospital networks (Max, Fortis, Apollo level) can introduce 4baseCare to hospital systems that accelerate the in-hospital lab model without additional capital — making the position worth more than the cheque. Third, pharma-adjacent family offices can introduce 4baseCare to pharma BD teams for data-licensing discussions, creating a direct path to the highest-margin revenue stream. The risks for family offices: long holding period without a clear IPO catalyst (unlike Skyroot, where a rocket launch creates a natural liquidity event); founder dilution concern (20.33% after 8 rounds); and DPDP compliance uncertainty. Rupeia recommends: healthcare-sector or pharma-adjacent family offices with Rs 200+ Cr

RUPEIA 4BASECARE, SERIES B INDEPENDENT REPORT

investable assets, a 7-10 year horizon, and the capability to facilitate 1-2 hospital introductions. Allocation: 2-4% of the alternatives book. For Institutions (VC, PE, Corporate Strategics, DFIs, Insurance/Pension) For VC funds: 4baseCare at Series B is within range but requires the bull case — Rs 300-500 Cr revenue by FY29-30, platform monetisation active, pharma data deals signed. Base case (Rs 120-180 Cr revenue) gives 2- 4x on Rs 700 Cr post-money at 12-15x — marginal for funds requiring 3-5x. Funds already in from Series A (Speciale Invest, Yali Capital) have positions far below Rs 700 Cr — they have already achieved 5-10x paper gain. New VC investors at Series B need conviction in the bull case. For Corporate Strategics: Infosys is the natural model — its Rs 8.3 Cr (2024) + follow-on (2026) is a beachhead to understand whether OncoTwin can be packaged as an Infosys-delivered healthcare AI product to hospital clients globally. A formal Infosys distribution agreement (not confirmed) would be the highest-value corporate event — potentially Rs 50-100 Cr in revenue access for zero additional capital. For Pharma companies (Novartis, AstraZeneca India, Sun Pharma): a data-licensing deal ($5-50M per deal) is the appropriate structure — not equity; pharma companies buy data access, they do not take equity in clinical data providers. For DFIs (SIDBI, DST NIDHI, DBT Ignite): 4baseCare fits as a healthcare-sector deeptech receiving government innovation grants; the Maharashtra MoU signals government alignment. These non-dilutive sources should be maximised before each equity round. For Insurance and Pension funds: not investable pre-revenue-visibility. Wait for a BSE SME listing (likely FY28-30) when clinical utility is established and revenue > Rs 100 Cr.

17 RED FLAG LEDGER WITH KILL CONDITIONS

RED FLAG SEVERITY KILL CONDITION WHAT RESOLVES IT

FY25 Revenue < Rs 10 Cr with -93% CAGR CRITICAL If MCA P&L confirms < Rs 10 Cr with no restatement/reclassification explanation AND test volume is much lower than stated: all growth projections built on incorrect baseline.

Tofler FY24 + FY25 P&L download and reconciliation with test-volume data. DPDP 2023 compliance gap (cross-border transfer)

HIGH If DPDP Rules require patient re-consent or data localisation: international lab model may need restructuring, delaying international revenue 12-24 months. DPDP legal opinion from qualified data-protection counsel. Forward-compliant consent framework.

NABL/CAP lab accreditation unverified

MEDIUM-

HIGH If labs are unaccredited: hospital relationships technically non-compliant; reports legally inadmissible. NABL database + CAP directory search. Request certificates.

Founder dilution at 20.33% after 8 rounds MEDIUM If founders' effective diluted stake falls below 10-12% without ESOP refresh: motivation risk over the 5-7 year journey.

Request ESOP pool and vesting. Ensure ESOP refresh as condition. International expansion (8-10 countries) execution

risk

MEDIUM If 6+ countries fail to reach steady-state within 18 months: capital consumed with minimal revenue return. Stage expansion: 3-4 countries in 12 months, then evaluate.

OncoTwin MSK validation outcome unknown MEDIUM If MSK publishes a comparison showing OncoTwin underperforms: international pharma BD becomes much harder.

Monitor MSK iHub publications from the Jan 2026 cohort. Ask for interim results.

RUPEIA 4BASECARE, SERIES B INDEPENDENT REPORT

18 RUPEIA FINAL INDEPENDENT VIEW

4baseCare is building something genuinely important: the definitive clinical genomics dataset for non- Caucasian cancer patients. The structural thesis — 70% of cancers in populations with <5% of genomic

research data — is scientifically valid, commercially exploitable, and defensible over a 10-year horizon. The

MSK iHub selection, ACTREC-Tata Memorial collaboration, Infosys strategic investment, and Maharashtra government MoU all validate that the clinical and institutional world is taking 4baseCare seriously.

ONE FATA LUNCER TA INTY

The investment case has one fatal uncertainty: the FY25 revenue anomaly. Everything else can be discussed, debated, and risk-weighted. But until the < Rs 10 Cr FY25 MCA revenue figure is reconciled with the 1,500 tests/month operational claim, no investor can trust the financial baseline. This single item must be resolved via direct MCA P&L verification before any capital commitment. If it resolves in favour of higher actual revenue (reclassification or accounting adjustment), this is a Series B biotech with genuine differentiation at a reasonable valuation. If it reveals test volume was substantially lower than claimed in FY25, all projections need rebuilding from a lower base.

RUPEIAVERDICT

The revenue anomaly flagged in Section 4 is not a footnote — it is the most important fact in this report. Resolve it before committing capital. 4baseCare is building the right product for the right

market. The question is whether the financial foundation is solid enough to trust the building.

Download the Tofler P&L. Then decide.

19 SOURCE LOG

REF SOURCE DATE KEY DATA CONFIDENCE

[1] BW Disrupt Jun 2026 Rs 38 Cr top-up; Rs 128 Cr total Series B; growX lead; hospital expansion; OncoTwin scale-up HIGH [2] Entrackr Jun 2026 Rs 128 Cr Series B confirmed; growX + Infosys top-up HIGH [3] analyticsinsight.net Jun 2026 Infosys Rs 8.3 Cr (2024); 1,500 tests/month; 8,000-10,000 target; 80% from testing

MEDIUM

[4] Medical Buyer Jun 2026 AIIMS Jammu + Max + Shankara partnerships; in-hospital lab model

MEDIUM

[5] digitalhealthnews.com Jan 2026 OncoTwin selected for MSK iHub; Series B Rs 90 Cr first close MEDIUM [6] whalesbook.com / press Feb 2026 Non-Caucasian gap (70%/<5%); Foundation/Guardant

comparison; 80% from testing

MEDIUM

[7] Tracxn (legal entity) Jun 2026 CIN U74999KA2018PTC112818; Founded May 3, 2018; 270 employees (+31%); FY25 < Rs 10 Cr; cap table

MEDIUM

[8] Express Healthcare Mar 31, Maharashtra Government MoU for precision oncology centre HIGH

RUPEIA 4BASECARE, SERIES B INDEPENDENT REPORT

REF SOURCE DATE KEY DATA CONFIDENCE

[9] nasscom.coe-iot.com Post- TarGT Indiegene; ACTREC-Tata Memorial; Illumina Accelerator 10th cohort; Karnataka Elevate grant

MEDIUM

[10] 4basecare.com (website) Jun 25, Product descriptions; lab locations; hospital partner names; technology claims

LOW-MEDIUM

[11] Tracxn (financials) Jun 2026 $25.9M total raised; 8 rounds; 43 investors; "Revenue CAGR -93% last 1 year"

MEDIUM

[12] NOT ACCESSED —

MANDATORY

— Tofler FY24 + FY25 P&L. NABL/CAP directories. DPDP legal opinion. ESOP pool and vesting.

NOT ACCESSED

The Standard This report was written without access to the company data room. Every figure is independently

sourced. Where evidence was insufficient, this report says so. The revenue anomaly flagged in Section 4

is not a footnote — it is the most important fact in this report. Resolve it before committing capital. 4baseCare is building the right product for the right market. The question is whether the financial foundation is solid enough to trust the building.

DISCLAIMER

This document is published strictly for informational, educational, and academic record-keeping purposes only. The publisher of this document is not a SEBI Registered Investment Adviser (RIA), nor a SEBI Registered Research Analyst (RA). This report does not constitute personal investment advice, an independent research report, a financial recommendation, or an offer or solicitation to buy, sell, or subscribe to any securities. Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.

RUPEIA | INDEPENDENTREPORT # 0 0 3 O F 1 0 0 | 4 BASECARESERIESB | JUNE 2 5 , 2 0 2 6

RUPEIA 4BASECARE, SERIES B INDEPENDENT REPORT